Higher Risk patients under Hypomethylating Agents- A multicentric experience from latin America

LAZZARINO, CAROLINA; RIVAS, MARÍA M; POSSE COBARCO, JUAN; CRISP, RENÉE; VIÑUALES, SUSANA; CAMPESTRI, REINALDO; BELLI, CAROLINA; BASQUIERA, ANA L; FERNANDEZ, VANESA; GONZALEZ, JACQUELINE; ESPINOSA, DANIEL; CABREJO, MARÍA; IASTREBNER, MARCELO; ARBELBIDE, JORGE; PINTOS, NOEMÍ; PRATES, M VIRGINIA; ALFONSO, GRACIELA; NARBAITZ, MARINA; GRILLÉ, SOFÍA

Valencia

Simposio; 14th Symposium on Myelodysplastic Syndromes; 2017

Myelodysplastic Foundation

Introduction: Hypomethylating agents (HMA), azacitidine (AZA) and decitabine (DAC) have been approved by the FDA as the first line option for higher risk MDS in 2007 based on their survival improvement for those patients. Since little is known about their use in Latin American (LA), in this sub-analysis, our aim was to examine the outcome of LA higher risk MDS patients under HMA treatment. Patients and Methods: We selected 109 (49%) higher risk patients from a multicentric retrospective LA database of 221 who initiated treatment between January-07/December-16. Higher Risk patients were defined according to the 74-IPSS, 20-CPSS (for CMML), 12-secondary MDS and other 3-MPD/MDS, showing no differences regarding survival under HMA therapy (p=0.354).Results: Higher risk patients showed a median age of 69 (range 19-70) years being 78% older than 60 years old, 64% were males, 60% performance status >0, 62% with co-morbidities, 82% hemoglobin level